Currently, most of the warning information about GLP-1RA comes from clinical trials or case reports, and only a limited number of pharmacovigilance studies have explored other adverse reactions of this kind of drug (23, 24)

Cignas typical PA requirements for Wegovy include: BMI documentation Documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea Comorbidity documentation If your BMI is between 27 and 30, your clinician must provide clinical evidence of at least one qualifying comorbidity and explain why weight reduction would improve that condition Clinical evaluation Documentation of a thorough clinical evaluation, including weight history, prior weight management attempts, and current health status Prescriber qualifications The prescriber must have appropriate authority and, in some plans, must be a specialist or part of a weight management program Prior authorization is a documentation requirement, not a denial
5 Given these uncertainties, pharmacological interventions like GLP-1 receptor agonists, such as semaglutide (Ozempic), have gained attention for weight loss
My advise is dont hesitate, Vitastir is the real deal
Available online: [DOI] [PubMed] [Google Scholar] 7.Liampas A., Velidakis N., Georgiou T., Vadalouca A., Varrassi G., Hadjigeorgiou G.M., Tsivgoulis G., Zis P